Lumos Pharma (FRA:4NX1) Interest Expense : €0.00 Mil (TTM As of Mar. 2024)

View and export this data going back to 2011. Start your Free Trial

What is Lumos Pharma Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Lumos Pharma's interest expense for the three months ended in Mar. 2024 was € 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was €0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Lumos Pharma's Operating Income for the three months ended in Mar. 2024 was € -9.99 Mil. Lumos Pharma's Interest Expense for the three months ended in Mar. 2024 was € 0.00 Mil. GuruFocus does not calculate Lumos Pharma's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Lumos Pharma Interest Expense Historical Data

The historical data trend for Lumos Pharma's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lumos Pharma Interest Expense Chart

Lumos Pharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-0.05

Lumos Pharma Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial															-	-	-	-	-

Lumos Pharma Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

Lumos Pharma (FRA:4NX1) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Lumos Pharma's Interest Expense for the three months ended in Mar. 2024 was €0.00 Mil. Its Operating Income for the three months ended in Mar. 2024 was €-9.99 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was €0.21 Mil.

Lumos Pharma's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

GuruFocus does not calculate Lumos Pharma's interest coverage with the available data.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Lumos Pharma Inc has enough cash to cover all of its debt. Its financial situation is stable.

Lumos Pharma (FRA:4NX1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lumos Pharma Inc (FRA:4NX1) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

LUMO:USA

Address

4200 Marathon Boulevard, Suite 200, Austin, TX, USA, 78756

Website

https://www.lumos-pharma.com

Lumos Pharma Inc is a biopharmaceutical company that develops treatments for cancer and rare diseases. It carries out both clinical-stage and preclinical research on a range of molecules that help the immune system fight off cancer cells. The treatments are available orally and can be used in conjunction with other cancer therapies. The company also researches an Ebola vaccine. Lumos contracts with manufacturing organizations to make their treatments, engages in partnerships with pharmaceutical companies, and operates primarily in the United States.

Lumos Pharma (FRA:4NX1) Headlines

No Headlines